Monoclonal antibody therapy of pancreatic cancer with cetuximab: Potential for immune modulation

Journal of Immunotherapy

Volumn 35, Issue 5, 2012, Pages 367-373

  Luedke, Eric ^a   Jaime Ramirez, Alena Cristina ^b   Bhave, Neela ^c   Carson III, William E ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b Ohio Integrated Biomedical Sciences Graduate Program   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Cetuximab; Interferon ; Interleukin 21; NK cells

Indexed keywords

CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEMCITABINE; OXALIPLATIN; PROTEIN TYROSINE KINASE;

ACNE; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ASEPTIC MENINGITIS; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; COLORECTAL CARCINOMA; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DYSPNEA; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HEAD AND NECK CARCINOMA; HUMAN; HYPERSENSITIVITY REACTION; IMMUNOMODULATION; INFECTION; LUNG CANCER; METASTASIS; NAUSEA; NEUTROPENIA; NONHUMAN; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RASH; REVIEW; SIGNAL TRANSDUCTION; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; TUMOR VASCULARIZATION; VOMITING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; CLINICAL TRIALS AS TOPIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOTHERAPY; PANCREATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SURVIVAL RATE; TREATMENT FAILURE;

EID: 84861235171     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3182562d76     Document Type: Review

References (72)

1. Kullmann F, Hollerbach S, Dollinger MM, et al. Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicenter phase II study. Br J Cancer. 2009;100:1032-1036.
2. Tempero M. Pancreatic cancer: introduction. Semin Oncol. 2007;34:283. (Pubitemid 47176625)
3. Burris HA III, Moore MJ, Anderson J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: a randomized trial. J Clin Oncol. 1997;15:2403-2413. (Pubitemid 27251144)
4. Olayioye MA, Neve RM, Lane HA, et al. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000;19:3159-3167. (Pubitemid 30428195)
5. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 2008;358:1160-1174.
6. Hynes N, Lane H. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5:341-354. (Pubitemid 40637826)
7. Cascinu S, Berardi R, Labianca R, et al. Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomized, mulicentre, phase II trial. Lancet Oncol. 2008;9: 39-44.
8. Xiong HQ, Rosenberg A, LoBuglio A, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. J Clin Oncol. 2004;22:2610-2616. (Pubitemid 41103748)
9. Blattman JN, Greenberg PD. Cancer immunotherapy: a treatment for the masses. Science. 2004;305:200-205. (Pubitemid 38886725)
10. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567-578. (Pubitemid 43209104)
11. Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007;25:2171-2177. (Pubitemid 46954639)
12. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer. N Engl J Med. 2004; 351:337-345. (Pubitemid 38944402)
13. Saltz LB, Meropol NJ, Loehrer PJ, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004;22:1201-1208. (Pubitemid 41079832)
14. Jonker D, O'Callaghan C, Karapetis C, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007;357: 2040-2048. (Pubitemid 350106711)
15. Wu X, Fan Z, Masui H, et al. Apoptosis induced by an antiepidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J Clin Invest. 1995;95:1897-1905.
16. Baselga J. The EGFR as a target for anticancer therapy-focus on cetuximab. Eur J Cancer. 2001;37:S16-S22. (Pubitemid 32938125)
17. Overholser JP, Prewett MC, Hooper AT, et al. Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer. 2000;89:74-82. (Pubitemid 30451276)
18. Buchsbaum DJ, Bonner JA, Grizzle WE, et al. Treatment of pancreatic cancer xenografts with erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation. Int J Radiat Oncol Biol Phys. 2002;4:1180-1193. (Pubitemid 35292632)
19. Bruns CJ, Harbison MT, Davis DW, et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res. 2000;6:1936-1948. (Pubitemid 30305093)
20. Baselga J, Pfister D, Cooper MR, et al. Phase I studies of antiepidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol. 2000;18:904-914. (Pubitemid 30106623)
21. Fracasso PM, Burris H 3rd, Arquette MA, et al. A phase I escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamics rationale for dosing. Clin Cancer Res. 2007;13:986-993. (Pubitemid 46340377)
22. Arnoletti JP, Frolov A, Eloubeidi M, et al. A phase I study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally advanced pancreatic cancer. Cancer Chemother Pharmacol. 2011;67:891-897.
23. Su X, Lacouture ME, Jia Y, et al. Risk of high-grade skin rash in cancer patients treated with cetuximab-an antibody against epidermal growth factor receptor: systemic review and metaanalysis. Oncology. 2009;77:124-133.
24. Ho C, Sangha R, Beckett L, et al. Escalating weekly doses of cetuximab and correlation with skin toxicity: a phase I study. Invest New Drugs. 2011;4:680-687.
25. Merchan JR, Ferrell A, Macintyre J, et al. Phase II study of gemcitabine, oxaliplatin, and cetuximab in advanced pancreatic cancer. Cancer Chemother Pharmacol. 2000;67:891-897.
26. Philip PA, Benedetti J, Corless C, et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-Directed Intergroup Trial SO205. J Clin Oncol. 2010;28:3605-3610.
27. Yamanaka Y, Friess H, Kobrin MS, et al. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res. 1993;13:565-569.
28. Fan Z, Shang BY, Lu Y, et al. Reciprocal changes in p27 (Kip1) and p21(Cip1) in growth inhibition mediated by blockade or overstimulation of epidermal growth factor receptors. Clin Cancer Res. 1997;3:1943-1948. (Pubitemid 27505119)
29. Prewett MC, Hooper AT, Bassi R, et al. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res. 2002;8:994-1003. (Pubitemid 34517632)
30. Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res. 2000;6:2166-2174. (Pubitemid 30399181)
31. Luwor RB, Lu Y, Li X, et al. The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression. Oncogene. 2005;24:4433-4441. (Pubitemid 40961766)
32. O-charoenrat P, Modjtahedi H, Rhys-Evans P, et al. Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells. Cancer Res. 2000;60:1121-1128. (Pubitemid 30129555)
33. Stavenhagen JB, Gorlatov S, Tuaillon N, et al. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fc gamma receptors. Cancer Res. 2007;67:8882-8890. (Pubitemid 47437465)
34. Clynes RA, Towers TL, Presta LG, et al. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000;6:443-446. (Pubitemid 30208162)
35. Fan Z, Masui H, Altas I, et al. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res. 1993;53:4322-4328. (Pubitemid 24146785)
36. Ciardiello F, Bianco R, Caputo R, et al. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res. 2004;10:784-793. (Pubitemid 38174017)
37. Musolino A, Naldi N, Bortesi B, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neupositive metastatic breast cancer. J Clin Oncol. 2008;26: 1789-1796.
38. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99: 754-758. (Pubitemid 34525533)
39. Robertson RJ, Ritz J. Biology and clinical relevance of human natural killer cells. Blood. 1990;76:2421-2438.
40. Vilches C, Parham P. KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annu Rev Immunol. 2002;20:217-251. (Pubitemid 34293425)
41. Bhave NS, Carson WE. The role of natural killer cells in innate immunity. In: Marsh ST, Piper M, eds. Regulation of Innate Immune Function. ISBN: 978-81-7895-492-9. Kerala, India: Transworld Research Network; 2010:141-164.
42. Carson WE, Giri JG, Lindemann MJ, et al. Interleukin-15 is a novel cytokine which activates human natural killer cells via components of the interleukin-2 receptor. J Exp Med. 1994;180:1395-1403. (Pubitemid 24289613)
43. Carson WE, Lindemann MJ, Baiocchi RA, et al. The functional characterization of IL-10 receptor expression on human natural killer cells. Blood. 1995;85:3577-3585.
44. Fehniger TA, Shah MH, Turner MJ, et al. Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. J Immunol. 1999;162:4511-4520. (Pubitemid 29314849)
45. Somersalo K, Carpen O, Saksela E. Stimulated natural killer cells secrete factors with chemotactic activity, including NAP-1/IL-8, which supports VLA-4-and VLA-5-mediated migration of T lymphocytes. Eur J Immunol. 1994;24:2957-2965.
46. Bluman EM, Bartynski KJ, Avalos BR, et al. Human natural killer cells produce abundant macrophage inflammatory protein-1 alpha in response to monocyte-derived cytokines. J Clin Invest. 1996;97:2722-2727. (Pubitemid 26197715)
47. Parihar R, Dierksheide J, Hu Y, et al. The natural killer cell cytokine response to antibody-coated tumor cells: enhancement by interleukin-12 and a role for monocytes. J Clin Invest. 2002;110:983-992.
48. Jaime-Ramirez AC, Mundy-Bosse BL, Kondadasula S, et al. IL-12 enhances the antitumor actions of traztuzumab via NK cell IFN-g production. J Immunol. 2011;186:3401-3409.
49. Parihar R, Nadella P, Lewis A, et al. A Phase I Study of interleukin-12 with trastuzumab in patients with HER2-overexpressing malignancies: correlation between response and sustained interferon-gamma production. Clin Cancer Res. 2004;10:5027-5037. (Pubitemid 39099777)
50. Roda JM, Parihar R, Carson WE III. CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells. J Immunol. 2005;175:1619-1627. (Pubitemid 41023064)
51. Roda JM, Parihar R, Lehman A, et al. Interleukin-21enhances NK cell activation in response to antibody-coated targets. J Immunol. 2006;177:120-129. (Pubitemid 43939123)
52. Roda JM, Parihar R, Magro C, et al. Natural killer cells produce T cell-recruiting chemokines in response to antibodycoated tumor cells. Cancer Res. 2006;66:517-526. (Pubitemid 43166061)
53. Roda JM, Joshi T, Butchar JP, et al. The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines. Clin Cancer Res. 2007;13:6419-6428. (Pubitemid 350075032)
54. Kondadasula SV, Roda JM, Parihar R, et al. Colocalization of the IL-12 receptor and FcgammaRIIIa to natural killer cell lipid rafts leads to activation of ERK and enhanced production of interferon-gamma. Blood. 2008;111: 4173-4183.
55. Bekaii-Saab TS, Roda JM, Guenterberg KD, et al. A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies. Mol Cancer Ther. 2009;8:2983-9140.
56. Mani A, Roda J, Young D, et al. A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients with metastatic breast cancer (MBC) who have previously failed trastuzumab. Breast Cancer Res Treat. 2009;117:83-89.
57. di Carlo E, de Totero D, Piazza T, et al. Role of IL-21 in immune regulation and tumor immunotherapy. Cancer Immunol Immunother. 2007;56:1323-1334. (Pubitemid 47024717)
58. Brady J, Hayakawa Y, Smyth MJ, et al. IL-21 induces the functional maturation of murine NK cells. J. Immunol. 2004;172:2048-2058. (Pubitemid 38182350)
59. Burgess SJ, Marusina AI, Pathmanathan I, et al. IL-21 downregulates NKG2D/DAP10 expression on human NK and CD8+ T cells. J. Immunol. 2006;176:1490-1497. (Pubitemid 43134292)
60. Moroz A, Eppolito C, Li Q, et al. IL-21 enhances and sustains CD8+ T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21. J Immunol. 2004;173:900-909. (Pubitemid 38924263)
61. Zeng R, Spolski R, Finkelstein SE, et al. Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J Exp Med. 2005;201:139-144.
62. Bolesta E, Kowalczyk A, Wierzbicki A, et al. Increased level and longevity of protective immune responses induced by DNA vaccine expressing the HIV-1 Env glycoprotein when combined with IL-21 and IL-15 gene delivery. J Immunol. 2006;177:177-191. (Pubitemid 43941648)
63. Bhave NS, Carson WE III. Immune modulation with interleukin-21. Cytokine Therapies. 2009;1182:39-46.
64. Jahrsdorfer B, Blackwell SE, Wooldridge JE, et al. B-chronic lymphocytic leukemia cells and other B cells can produce granzyme B and gain cytotoxic potential after interleukin-21-based activation. Blood. 2006;108:2712-2719.
65. Pesce J, Kaviratne M, Ramalingam TR, et al. The IL-21 receptor augments Th2 effector function and alternative macrophage activation. J Clin Invest. 2006;116:2044-2055. (Pubitemid 44033328)
66. Strengell M, Sareneva T, Foster D, et al. IL-21 up-regulates the expression of genes associated with innate immunity and Th1 response. J Immunol. 2002;169:3600-3605.
67. Thompson JA, Curti BD, Redman G, et al. IL-21: tolerability and anti-tumor activity following two 5-day cycles in patients with stage IV melanoma or renal cell carcinoma. Proc Am Soc Clin Onc. 2006;24:101s. abstract no. 2505.
68. Davis ID, Skrumsager BK, Cebon J, et al. An open-label, twoarm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma. Clin Cancer Res. 2007;13:3630-3636. (Pubitemid 46955126)
69. Milas L, Mason K, Hunter N, et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res. 2000;6:701-708. (Pubitemid 30111496)
70. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567-578. (Pubitemid 43209104)
71. Prewett M, Hooper A, Bassi R, et al. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res. 2002;8:994-1003. (Pubitemid 34517632)
72. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-345. (Pubitemid 38944402)